title: Ochroconis gallopavum infection in a lung transplant recipient: report of a case.
abstract: Disseminated phaeohyphomycoses are rare infections caused by dematiaceous fungi. Ochroconis gallopavum is a neurotropic dematiaceous mold responsible for life-threatening respiratory and central nervous system infections in domestic poultry and in immunologically compromised humans. The world literature describes only 13 previous O gallopavum infections in solid organ transplant recipients. We report herein an O gallopavum phaeohyphomycosis with involvement of skin in a transplant recipient. A 69-year-old white man with a history of bilateral lung transplantation 6 years ago presented with acute onset of severe respiratory distress. Chest X-ray showed no evidence of pneumonia. Lung function showed bronchiolitis obliterans syndrome. Excision biopsy was performed because of a suspected pigmented basal cell carcinoma. Histopathology revealed dermal granulomatous dermatitis, focally suppurative, dominated by epitheloid cells with brownish round fungi. Further microbiological work-up of the biopsy specimen subsequently revealed O gallopavum as the causative organism. No brain involvement was observed. Antimycotic therapy with voriconazole 200 mg twice a day was immediately initiated and the patient was treated for 3 months. Additional intravenous therapy with tobramycin and imipenem was started upon detection of Enterobacter clocae and Enterococci in the sputum. The patient recovered during the next few weeks and was discharged on day 26.
authors.affiliation: Department of Dermatology, University Hospital Essen, Essen, Germany. eirini.brokalaki@uk-essen.de
authors.forename: E I
authors.initials: EI
authors.lastname: Brokalaki
authors.forename: U
authors.initials: U
authors.lastname: Sommerwerck
authors.forename: E H
authors.initials: EH
authors.lastname: von Heinegg
authors.forename: U
authors.initials: U
authors.lastname: Hillen
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000935:Antifungal Agents / Q000008:administration & dosage; D001706:Biopsy; D001989:Bronchiolitis Obliterans / Q000209:etiology; D018450:Disease Progression; D004334:Drug Administration Schedule; D016972:Enterobacter cloacae / Q000302:isolation & purification; D016983:Enterococcus / Q000302:isolation & purification; D017809:Fatal Outcome; D006801:Humans; D015378:Imipenem / Q000008:administration & dosage; D016040:Lung Transplantation / Q000009:adverse effects*; D008297:Male; D009894:Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D060446:Phaeohyphomycosis / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D011743:Pyrimidines / Q000008:administration & dosage; D012141:Respiratory Tract Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology; D012867:Skin / Q000382:microbiology* / Q000473:pathology; D013183:Sputum / Q000382:microbiology; D014031:Tobramycin / Q000008:administration & dosage; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage; D065819:Voriconazole
chemical_list: D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D015378:Imipenem; D065819:Voriconazole; D014031:Tobramycin